Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ)

2016-12-19

Today on 19 December 2016 at Enzymatica's extraordinary general meeting in Lund, the meeting resolved on the number of members of the board of directors, election of new members of the board of directors and remuneration to new board members.

Election of new members of the board of directors
The meeting resolved in accordance with the shareholder proposal that the board of directors, for the period until the next annual general meeting, shall consist of six ordinary board members without deputy board members. The meeting resolved that the current ordinary board members Lennart Nilsson, Hans Pihl, Nils Siegbahn and Monica Wallter are dismissed and that Bengt Baron, Mats K Andersson and Louise Nicolin are elected as new ordinary board members along with existing ordinary board members. Bengt Baron was elected chairman of the board. Consequently, the members of the board of directors do hereafter consist of Bengt Baron (chairman), Marianne Dicander Alexandersson, Mats K Andersson, Louise Nicolin, Guðmundur Pálmason and Sigurgeir Guðlaugsson.

Remuneration to new board members
Remuneration to newly elected ordinary board members was resolved to be paid in the same amounts (pro rata) as resolved for the chairman of the board of directors and the ordinary board members by the annual general meeting 2016, i.e. SEK 180,000 for the chairman and SEK 120,000 to every other member of the board of directors (on annual basis).

For more information, please contact:

Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com

This information is information that Enzymatica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 0920 CET on August 30, 2016.

About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on seven markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.   

Enzymaticas Certified Adviser is Erik Penser Bankaktiebolag.